Evolocumab Reduced CV Events in Diabetes - Top_Thought_Leaders - MDSpire

Evolocumab Reduced CV Events in Diabetes

Subgroup analysis of the VESALIUS-CV trial supports earlier intensive lipid lowering

  • By

  • Kathryn Wighton

  • April 1, 2026

  • 4 min

Share

Top Thought Leaders in Neurology

Brief introduction explaining scope and methodology.

Original Source(s)

Evolocumab Reduced CV Events in Diabetes

  • by Kathryn Wighton

  • April 1, 2026

Related Content

FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Cardiac intimal sarcoma presenting as basilar artery occlusion treated with tenecteplase and thrombectomy: a case report

Biomolecular mechanisms of cardiac amyloidosis and its cardiovascular pathological basis